Media

MetaGenoPolis-INRAE is committed alongside major healthcare players in France to accelerate the development of precision medicine.
Coordinated by Imagine Institute and funded with 9,9 million of euros over 5 years, ATRACTion program aims to develop a precision medicine for patients with autoimmune and inflammatory diseases associated with primary immune deficiencies.

MetaGenoPolis-INRAE, center expert in human and animal microbiome research, announces to have been received with other co-investigators new funding from the Aligning Science Across Parkinson’s (ASAP) initiative to investigate the role of the microbiome in phenotypic conversion to Parkinsons disease in a genetically susceptible population. This project, named “Genome-Microbiome Axis in the Cause of Parkinson Disease: Mechanistic Insights and Therapeutic Implications from Experimental Models and a Genetically Stratified Patient Population” will involve the scientific and technical expertise of MetaGenoPolis-INRAE in the field of the microbiome.

MetaGenoPolis (MGP) is proud and excited to announce the creation of its Strategic External Committee (CES).
The newly formed CES will closely work with MetaGenoPolis management team. MGP will continue to advance the development of its offers in microbiome research.

launched by Bpifrance and its recognition as a "French Tech Seed" business contributor in February 2020, the AgriO consortium proposes a new labeling process to young innovative companies looking for investors. Delivered by experts from the agricultural, agribusiness or agri-food industry worlds to high-potential young companies, the AgriO label completes the personalized support provided by specialized structures (incubators, accelerators, competitiveness clusters, etc.) that have pooled their expertise.

Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and BIOASTER, the French Technology Research Institute in applied microbiology, announced today the initiation of a collaborative project aiming to evaluate the immunomodulatory and homeostatic potential of the Microbiome Metabolic Therapies (MMT™) - de novo synthetized proprietary glycans developed by Kaleido to improve human health via the gut microbiome.